Sun Flags Up New Prescriptions Drought Amid COVID-19
But Situation Improving And Ilumya Solid
Executive Summary
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
You may also be interested in...
Sun Sees Indian Market Rebound
90%-95% of specialty doctors are back at their clinics in India and pharma field force personnel are again on the move, though patient footfall is yet to fully normalize, the country’s largest drug firm Sun has indicated. While the situation isn’t quite the same in the US, the company reported sales growth in both key geographies in Q3.
Physicians Return, Field Force Activity Nears Pre-Pandemic Levels In India
90-95% of specialty doctors are back at their clinics in India and pharma field force personnel are again on the move, though patient footfall is yet to fully normalize, the country’s largest drug firm Sun has indicated. While the situation isn’t quite the same in the US, the company reported sales growth in both key geographies in Q3.
Sun’s Ilumya To Claw Into Japanese Psoriasis Market
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.